Financial
FY2025 revenue €17.83bn (-1.0%); operating margin 8.0%; net income €895.0m.
Net debt €5.29bn.
HQ Netherlands · Europe
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
FY2025 revenue €17.83bn (-1.0%); operating margin 8.0%; net income €895.0m.
Net debt €5.29bn.
Source: official results release · Year ended 2025-12-31 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025 | €17.8bn | -1.0% | €1.4bn | €895m | Koninklijke Philips |
Products not yet catalogued.
FY2025 revenue €17.83bn (-1.0%); operating margin 8.0%; net income €895.0m.
Net debt €5.29bn.
Aug 2026: ransomware group Cl0p claimed to have taken about 13.5GB of mostly technical drawings. Philips said it contained an attempted compromise of one internal server, with no customer impact.
Aug 2026: attempted compromise of an internal enterprise server (Cl0p claim); Philips said it was contained with no customer impact. NHS DSPT and certification status not yet checked.
Under a 2024 US FDA/DOJ consent decree following the June 2021 Respironics CPAP/BiPAP recall, Philips cannot sell new sleep and respiratory care devices in the US until its facilities comply. Ventilator remediation and testing were still ongoing in May 2026.
No contract terminations or disputes involving Philips found in HSH's search of the last 24 months.
No competitors linked yet.